Phase 4 N=66 High-dose vs. Standard-dose Cephalexin for Cellulitis
Cellulitis
Primary: Patient Recruitment Rate — 51.5 percentage of eligible patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis
Cellulitis
Primary: Visual Analog Scale(VAS) for Pain - Day 1 to 48 Hours — 79.64; 56.45; 39.71; 25.91 score on a scale
N/A N=230 The Personalised Antibiotic Duration for Cellulitis (PAD-C) Study
Cellulitis · Cellulitis of Leg · Antibiotic Duration
Primary: Sustained Recovery — 156 Participants
N/A N=153 Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients
Cellulitis
Primary: Relative Efficacy — 62; 60 participants — p=<0.05
Phase 2 N=206 Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis
Cellulitis
Primary: The Number of Patients Failing Therapy After 72 Hours of Antibiotic Treatment With Oral Cephalexin or Intravenous Cefazolin Plus Oral Probenecid. — 6; 4 Participants
Phase 4 N=100 Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections
Cellulitis · Skin Infections
Primary: Satisfaction of Discharge Criteria — 15; 14 participants
Phase 2 N=259 EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Number of Participants That Were 2-level Composite (CR-PCSS and PR-PCSS) Responders During the Observation Phase — 19; 0; 16; 0 Participants
Phase 2 N=64 Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)
Edematous Skin
Primary: Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 22 — 1.08; 1.10; 0.75; 0.50 score on a scale
Phase 2 N=1,310 Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Phase 2 N=375 EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Percentage of Composite Responders of at Least 2-Level Improvement of Severity — 20; 3 Participants
Phase 3 N=483 Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 58; 29; 43; 45 Participants
Phase 2 N=35 CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
Edematous Fibrosclerotic Panniculopathy · Cellulite · Laxity; Skin
Primary: Percentage of 1-Level Responders (+1 or Better Score) on the Investigator-Global Aesthetic Improvement Scale (I-GAIS) for Either Buttock or Either Thigh — 85.7; 87.5…
Phase 3 N=153 Real World CCH Study in Adult Females With Cellulite
Edematous Fibrosclerotic Panniculopathy (EFP) · Cellulite
Primary: The Proportion of Participants With Improved (+1 or Better) Score on I-GAIS for Either Posterolateral Thigh — 58 Participants
Phase 2 N=150 A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy
Edematous Fibrosclerotic Panniculopathy (EFP)
Primary: Investigator Global Assessment of Aesthetic Improvement — 0.7; 0.9; 1.1; 0.5 units on a scale
Phase 3 N=679 Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
Acute Bacterial Skin and Skin Structure Infections
Primary: Early Clinical Response — 306; 303 Participants
Phase 2 N=150 Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections
Bacterial Infection
Primary: Clinical Response at the Test of Cure (TOC) Visit in the Modified Intent-to-treat (MITT) Population — 84.7; 88.9 percentage of participants
Phase 3 N=761 Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
Complicated Skin and Soft Tissue Infection
Primary: Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis Set — 396; 202; 58; 34 Participant
Phase 2 N=122 Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Infections, Bacterial
Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…
Phase 3 N=698 Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
Bacterial Infections
Primary: Clinical Cure Rate at Test of Cure (TOC) (MITT Population) — 304; 297; 29; 21 participants
Phase 3 N=680 Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
Bacterial Infections
Primary: Clinical Cure Rate at Test of Cure (TOC) (MITT Population) — 291; 289; 25; 28 participants
N/A N=139 Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
Phase 2 N=200 A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
Major Cutaneous Abscess · Cellulitis · Erysipelas
Primary: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 91 participants
Phase 4 N=200 Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
Staphylococcal Infection · Abscess · Staphylococcal Skin Infection
Primary: Clinical Improvement at the 48-72 Hour Clinical Follow-up — 94; 97 participants
Phase 4 N=1,077 Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
Skin/Soft Tissue Infections · Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…
Phase 4 N=161 Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
Skin Diseases, Infectious
Primary: Skin Abscess Resolution — 4; 3 participants
Phase 4 N=5 To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite.
Cellulite
Primary: Proportion of Subjects With ≥1-point Improvement on Investigator Global Aesthetic Improvement Scale (I-GAIS) at Day 90 (Buttocks) — 3; 2 Participants
Phase 1 N=16 Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
Diabetes · Wound Infection · Healthy Volunteers
Primary: Ceftolozane Tissue Penetration — 0.75; 0.87 ratio
N/A N=88 Efficacy of Buffered Lidocaine in Patients With Facial Swelling
Orofacial Swelling
Primary: Pain Measurement as Assessed on a Heft-Parker 170 mm Visual Analog Scale — 69.3; 59.2 units on a scale
Phase 2 N=201 Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Infections, Gram-positive Bacterial
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 74; 72; 3; 5 participants — p=0.5318
Phase 2 N=29 The Effect of the Cosmetic Cream NMBM on Leg Ulcers - a Pilot Study
Ulcer · Venous Ulcer · Skin Ulcer
Primary: Logarithm of Percentage of Baseline Ulcer Size — 3.6043; 3.5030 Mean of log (percentage of baseline area — p=0.652